Format

Send to

Choose Destination
Cancers (Basel). 2019 Apr 29;11(5). pii: E598. doi: 10.3390/cancers11050598.

Polymorphisms of Mismatch Repair Pathway Genes Predict Clinical Outcomes in Oral Squamous Cell Carcinoma Patients Receiving Adjuvant Concurrent Chemoradiotherapy.

Author information

1
Department of Public Health, School of Public Health, College of Public Health, Taipei Medical University, Taipei 11031, Taiwan. tsenghore@gmail.com.
2
Department of Nursing, School of Medicine and Allied Health Sciences, University of The Gambia, Independence Drive, Banjul, P. O. Box 1646, The Gambia. tsenghore@gmail.com.
3
Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei 11301, Taiwan. wangwc@tmu.edu.tw.
4
Department of Public Health, Chang Gung University, Taoyuan 33305, Taiwan. kathy.htchien@gmail.com.
5
Department of Nutrition and Health Sciences, Chang Gung University of Science and Technology, Taoyuan 33302, Taiwan. kathy.htchien@gmail.com.
6
Department of Public Health, School of Public Health, College of Public Health, Taipei Medical University, Taipei 11031, Taiwan. youxin810@gmail.com.
7
Department of Otolaryngology, Chang Gung Memorial Hospital, Keelung 20401, Taiwan. rioriorioman@gmail.com.
8
Department of Public Health, Chang Gung University, Taoyuan 33305, Taiwan. shiangfu.huang@gmail.com.
9
Department of Otolaryngology, Head and Neck Surgery, Chang Gung Memorial Hospital, Linkou, Taoyuan 33305, Taiwan. shiangfu.huang@gmail.com.
10
Department of Public Health, School of Public Health, College of Public Health, Taipei Medical University, Taipei 11031, Taiwan. ccyeh@tmu.edu.tw.
11
School of Public Health, College of Public Health, China Medical University, Taichung 40402, Taiwan. ccyeh@tmu.edu.tw.

Abstract

BACKGROUND:

We aimed to investigate the association between single-nucleotide polymorphisms (SNP) in mismatch repair (MMR) pathway genes and survival in patients with oral squamous cell carcinoma (OSCC) who received adjuvant concurrent chemoradiotherapy (CCRT).

METHODS:

Using the Sequenom iPLEX MassARRAY system, five SNPs in four major MMR genes were genotyped in 319 patients with OSCC who received CCRT treatment. Kaplan-Meier survival curves and Cox proportional hazard regression models were used to assess overall survival (OS) and disease-free survival (DFS) among MMR genotypes.

RESULTS:

The results of Kaplan-Meier survival analysis revealed that the MutS homolog 2 (MSH2) rs3732183 polymorphism showed a borderline significant association with DFS (log-rank p = 0.089). Participants with the MSH2 rs3732183 GG genotype exhibited a relatively low risk of recurrence (hazard ratio (HR) = 0.45; 95% confidence interval (CI) = 0.22-0.96; p = 0.039). In addition, the MutL homolog 1 (MLH1) rs1800734 GG genotype carriers exhibited higher OS (HR = 0.52, 95% CI = 0.27-1.01; p = 0.054) and DFS (HR = 0.49, 95% CI = 0.26-0.92; p = 0.028) rates.

CONCLUSIONS:

Our results indicated that the GG genotypes of MSH2 rs3732183 and MLH1 rs1800734 are associated with relatively high survival in OSCC patients treated using adjuvant CCRT. These polymorphisms may serve as prognosis predictors in OSCC patients.

KEYWORDS:

clinical outcome; concurrent chemoradiotherapy; mismatch repair gene; oral squamous cell carcinoma; single-nucleotide polymorphism

PMID:
31035658
DOI:
10.3390/cancers11050598
Free full text

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center